Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Beauty Claims "Blur" Difference From Drugs As Cosmeceutical Market Grows

Nov 22 2010

• By Lauren Nardella

Related Content

Public Citizen Takes On Propoxyphene Again, This Time Comes Out On Top

Feb 09 2009

CDER's Generational Shift: Many New Reviewers With Little Experience

Dec 14 2009

Cosmeceutical Claims May Be Headed Into FDA's Radar

Aug 10 2009

FDA Acetaminophen Options Have Unintended Consequences - Drug Makers

Jun 29 2009

Funding, Authority Questions Hinder Coverage With Evidence Development

Nov 23 2009

Merck Taking Aggressive Approach To Cardiovascular Development

Jan 05 2009

House Passes Food Safety Bill That May Not Be Appetizing To Senate

Aug 03 2009

FDA Takes Action Against Propoxyphene But Keeps It On The Market

Jul 07 2009

HBA Global Expo In Brief

Oct 04 2010

Egrifta Quality Of Life Deciding Factor In Advisory Panel's Recommendation

May 31 2010

The Risks Of Surrogacy: Egrifta Faces Twofold Challenge At Advisory Committee

May 25 2010

Provenge Poised For Broad Insurance Coverage, Despite Grumbles On Price

May 24 2010

Omnitrope’s Low Switch Rate Due To Inferior Delivery Device - Express Scripts

Nov 26 2007

Roche Exorcizes Torcetrapib’s Ghost: CETP Candidate Starts Phase III

May 01 2008

Package Certification Law Bears Down On Vitamins As Trade Groups Scramble

Nov 10 2008

Novartis Buys into New Pharma World Order

Dec 01 2005

Biogen Idec Taps Exelixis' Scangos To Be New CEO

Jul 01 2010

IFT Annual Meeting & Food Expo In Brief

Aug 02 2010

HHS CER Catalog May Not Be Sustainable Without Clear Funding Stream - NIH

Aug 23 2010

PCORI Should Take Lead On Public CER Inventory, Pharma Groups Tell HHS

Aug 23 2010

Prostate Cancer Market Snapshot: More Than Provenge

Nov 22 2010

Provenge Coverage With Data Collection Suggested By MEDCAC Members

Nov 22 2010

Provenge Outcomes Data "Moderately" Strong For Labeled Use; Off-Label Insufficient, AHRQ Tech Assessment Says

Nov 11 2010

New Products In Brief

Apr 26 2010

Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out

Jun 21 2010

With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use

Jun 21 2010

Incoming CHPA Head Melville Brings Pharma Resume To OTC Learning Curve

Oct 04 2010

POM Wonderful Defends Its Claims, Says FTC Action Is Persecution

Oct 04 2010

Prolia Pricing: Straddling Osteoporosis And Oncology

Jun 07 2010

Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard

Oct 25 2010

Presumed Guilty: HHS Exclusion Guidance Shifts Burden Of Proof To Corporate Officers

Oct 25 2010

Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors

Nov 08 2010

Provenge Off-Label Use Is Key CMS Concern In NCA, Dendreon Says

Aug 09 2010

Amgen Reflects Relief From Bundling Rules, Optimistism About Prolia

Jul 31 2010

Reata Sets Sights On 2012 Bardoxolone Launch With $78 Million Financing In Hand

Jul 12 2010

CMS Finally Gets An Administrator; Berwick In Until Late 2011, At Least

Jul 12 2010

Tamper-Resistance Could Allow New Opioid Formulations To Differentiate Themselves

Nov 01 2010

nContact Surgical Inc.

Jun 01 2010

China's Pro-science Leaders To Make Biotech Drugs A Central Plank In New Five Year Plan

Oct 13 2010

Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Dec 11 2006

Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO

Jun 11 2010

Novartis' Sandoz Unit Makes Respiratory Push With Acquisition Of Oriel

Apr 19 2010

Is Provenge "Reasonable And Necessary"? CMS Analysis For Medicare Coverage Seeks To Find Out

Jul 01 2010

FDA Crackdown On Anti-Aging Imports Signals "Major Enforcement Initiative"

Jun 07 2010

FDA Okays Amgen's Prolia, But With Hefty Post-Marketing Requirements In Tow

Jun 01 2010

Regulatory And Policy News, In Brief

Nov 22 2010

Sekisui Chemical To Acquire U.S. CRO XenoTech

Jul 10 2008

Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug

Sep 23 2010

Novartis Research Foundation's FMI Director Susan Gasser: An Interview With "The Pink Sheet" DAILY (Part 2 Of 2)

Sep 23 2010

Pfizer's Lewis-Hall To Represent Pharma Interests On PCORI Board

Sep 23 2010

Additional Topics

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window